Covance Expands Biotech Services to North America
Covance Inc. expands its biotechnology offerings into North America with the opening of a biotechnology services facility on its Greenfield campus in Indiana. This facility will use the expertise developed and offered by Covance in the United Kingdom for more than 20 years.
Earlier this year, Eli Lilly and Co. and Covance expanded their relationship with a three-year biotechnology services agreement, in which Lilly transferred bioproduct analytical testing to Covance. The Greenfield biotechnology services facility includes state-of-the-art analytical laboratories for protein chemistry, immunocharacterization, bioassay, stability studies, and release testing services. This facility has more than doubled Covance’s global biotechnology services footprint and it continues to expand. Covance is currently providing biotechnology services to Lilly as well as second major pharmaceutical client at the Greenfield site and is now accepting work from other clients.
Covance has provided biotechnology services at for the past 20 years at its Harrogate U.K. site. Over the last year alone, its industry-leading scientific and regulatory experts have supported more than 250 different biomolecules. This experience, coupled with the addition of top scientific, regulatory and operational talent, enabled Covance to quickly begin operations at the Greenfield facility. Covance has worked with more than 100 biopharmaceutical clients globally.
“The expansion of our high-quality biotechnology services from Europe to North America is a critical milestone for Covance to meet the growing biopharmaceutical development needs from our clients,” says Carl Martin, VP, Biotechnology, Covance. “With a dedicated team of experts in biological development and commercialization, and an unwavering commitment to operational and service excellence, Covance strives to provide clients with optimal solutions to bring their biotherapeutics to market.”